Position in GPCR
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$23,939,986
+$17,844,566 QoQ
Shares Held
446,059
+252.7% QoQ
Ownership
0.626%
of shares outstanding
% of Portfolio
4.08%
of 13F equity value
Holder Rank
#28
of 190 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 4%
Shared 0%
None 96%
Common Shares in GPCR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Davern Capital Partners, LP holds $543,745,809 across 13 Biotechnology names. GPCR ranks #9 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BNTX |
BioNTech SE
|
754,550 | $70,210,877 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
1,932,904 | $68,405,472 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,155,809 | $64,806,210 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
798,709 | $63,329,636 | |
| 5 | INSM |
INSMED Inc
|
559,824 | $59,688,434 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
92,640 | $57,764,745 | |
| 7 | LEGN |
Legend Biotech Corp
|
1,191,522 | $34,411,155 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
113,085 | $34,041,977 |
All Filings in GPCR
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,939,986 | 446,059 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $6,095,420 | 126,461 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||